

A retrospective multicenter study of the prognostic impacts of platelet augmentation and antiplatelet therapy on hepatoblastoma

Jun Zhang¹, Liling Han¹, Tang Xianglian², Chen Dong³, Kong Xiangru¹, and zhenzhen zhao¹

¹Department of Surgical Oncology Ministry of Education Key Laboratory of Child Development and Disorders National Clinical Research Center for Child Health and Disorders China International Science and Technology Cooperation Base of Child Development and Critical Disorders Children's Hospital of Chongqing Medical University Chongqing P R China Chongqing Key Laboratory of Pediatrics

²Department of Pediatric Surgery Hunan Children's Hospital Changsha People's Republic of China

³Department of General Surgery Xi'an Children's Hospital Affiliated to Xi'an Jiaotong University National Children's Northwest Regional Medical Center









July 20, 2022



Abstract

Background: Hepatoblastoma (HB) combined with secondary thrombocytosis is a common clinical condition. There is still no consensus on the need for antiplatelet therapy in patients with both HB and secondary thrombocytosis. **Methods:** We conducted a retrospective study of 229 children with HB who visited and were followed up at three hospitals from July 2013 to July 2019. Kaplan-Meier analysis was used to calculate overall survival (OS), the log-rank test was used to compare the survival rate between groups, and a multivariate Cox proportional hazards model was constructed to estimate the hazard ratios (HRs) of independent prognostic factors. **Results:** The one-year, three-year, and five-year OS of 229 children was 90.9, 83.0, and 79.7%, respectively. Multivariate analysis revealed that age >96 months, metastasis, antiplatelet therapy, and AFP<100ng/ml were independent risk factors for OS, while tumor rupture and PLT >450×10⁹/L were not. Among the intermediate-risk children in the high platelet group, the survival rate after antiplatelet therapy was 52.3±6.1%, which was significantly lower than that following non-antiplatelet therapy (82.6±5.1%) (*P*=0.036). **Conclusion:** Our findings confirm that secondary thrombocytosis is not an independent risk factor of OS in HB. We don't recommend antiplatelet therapy for children with hepatoblastoma combined with secondary thrombocytosis.

Hosted file

7-16.doc available at <https://authorea.com/users/496426/articles/577801-a-retrospective-multicenter-study-of-the-prognostic-impacts-of-platelet-augmentation-and-antiplatelet-therapy-on-hepatoblastoma>





Hosted file

table1.docx available at <https://authorea.com/users/496426/articles/577801-a-retrospective-multicenter-study-of-the-prognostic-impacts-of-platelet-augmentation-and-antiplatelet-therapy-on-hepatoblastoma>

Hosted file

table2.docx available at <https://authorea.com/users/496426/articles/577801-a-retrospective-multicenter-study-of-the-prognostic-impacts-of-platelet-augmentation-and-antiplatelet-therapy-on-hepatoblastoma>

